U.S., May 2 -- ClinicalTrials.gov registry received information related to the study (NCT07562581) titled 'A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC' on April 25.
Brief Summary: Aim to evaluate the efficacy and safety of luvometinib combined with anlotinib in patients with KRAS-mutated non-small cell lung caner
Study Start Date: June, 2026
Study Type: INTERVENTIONAL
Condition:
Non-small Cell Lung Caner
KRAS-mutated
Metastasis
Previous Treamted
Intervention:
BIOLOGICAL: luvometinib + anlotinib
Dose A：luvometinib 8mg and anlotinib 8mg; Dose B1：luvometinib 12mg and anlotinib 8mg; Dose B2: luvometinib 8mg and anlotinib 10mg; Dose C: luvometinib 12mg and anlotinib 10mg.
BIOLOGICAL: luvome...